MacroGenics Provides Update on Flotetuzumab Program in Acute Myeloid Leukemia
17 juil. 2019 16h01 HE
|
MacroGenics, Inc.
Enrollment of Phase 1 monotherapy expansion cohort completed; presentation of data expected 2H2019End of Phase 1 meeting requested with FDA to discuss program and future development plansInitiation of...
MacroGenics and I-Mab Announce Exclusive Collaboration and License Agreement to Develop and Commercialize Enoblituzumab in Greater China
10 juil. 2019 16h01 HE
|
MacroGenics, Inc.
ROCKVILLE, MD, and SHANGHAI, China, July 10, 2019 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative...
MacroGenics to Participate in Jefferies Healthcare Conference
30 mai 2019 07h30 HE
|
MacroGenics, Inc.
Rockville, MD, May 30, 2019 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal...
MacroGenics to Host Conference Call and Webcast to Review Margetuximab Phase 3 SOPHIA Study Presentation at ASCO
28 mai 2019 16h30 HE
|
MacroGenics, Inc.
Rockville, MD, May 28, 2019 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal...
MacroGenics Announces Positive Results from Phase 3 SOPHIA Study of Margetuximab in Patients with HER2-Positive Metastatic Breast Cancer
15 mai 2019 17h07 HE
|
MacroGenics, Inc.
Study meets first sequential primary endpoint of progression-free survival (PFS) in head-to-head with current standard of care (trastuzumab and chemotherapy)Oral abstract will be presented at American...
MacroGenics Provides Update on Corporate Progress and First Quarter 2019 Financial Results
01 mai 2019 16h01 HE
|
MacroGenics, Inc.
ROCKVILLE, Md., May 01, 2019 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal...
MacroGenics Announces Date of First Quarter 2019 Financial Results Conference Call
24 avr. 2019 16h30 HE
|
MacroGenics, Inc.
ROCKVILLE, MD, April 24, 2019 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal...
MacroGenics Reports Presentation of Data at the AACR Annual Meeting 2019
03 avr. 2019 16h30 HE
|
MacroGenics, Inc.
ROCKVILLE, MD, April 03, 2019 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal...
MacroGenics to Participate in Upcoming Investor Conferences
02 avr. 2019 17h00 HE
|
MacroGenics, Inc.
ROCKVILLE, MD, April 02, 2019 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal...